Singapore: Nasdaq-listed Sinovac Biotech has received GMP certification from the China State Food and Drug Administration (SFDA) for the company's dedicated mumps vaccine production plant at its Sinovac Dalian facility. The SFDA issued a public announcement on September 12, 2012, stating that the Good Manufacturing Practices (GMP) certification was issued to Sinovac with the certificate number CN20120080.

According to its CEO, Mr Weidong Yin, obtaining GMP certification for the mumps vaccine production facility is a significant milestone as it advances Sinovac's development pipeline and expands its portfolio of commercialized vaccines. "We are poised to leverage our established sales and marketing team and distribution network that covers over 1,000 clients at Centers of Disease Control and Points of Vaccination across China," said Mr Yin.

Sinovac is set to commence commercial production of the mumps vaccine in the third quarter 2012. "The company is on track to launch the mumps vaccine in China following the batch release process," informed Mr Yin.